Literature DB >> 2168857

An interleukin 1 inhibitor affects both cell-associated interleukin 1-induced T cell proliferation and PGE2/collagenase production by human dermal fibroblasts and synovial cells.

P Seckinger1, M T Kaufmann, J M Dayer.   

Abstract

Lipopolysaccharide (LPS) induces cell-associated interleukin 1 (IL 1) production in the human promonocytic cell line U937. Demonstration of cell-associated IL 1 activity was based on the ability of LPS-treated U937 cells, subsequently fixed with paraformaldehyde, to stimulate thymocyte proliferation in the presence of phytohemagglutinin. Like soluble IL 1 (sIL 1), cell-associated IL 1 is capable of inducing PGE2 and/or collagenase production by dermal fibroblasts and human synovial cells in a dose-dependent manner. It is thus a mediator of the inflammatory response owing to a direct intercellular contact located at the membrane level, where bound molecules may trigger inflammation at a local site of action. We reported that the natural (approximately 23 kDa) IL 1 inhibitor (IL 1 INH) from the urine of febrile patients inhibited all the sIL-1-induced biologic activities under investigation and that it acted by binding to the IL 1 receptor, thus blocking the interaction of the monokine with the receptor. Data demonstrate that the IL 1 INH also blocks cell-associated IL 1-induced T cell proliferation and PGE2 production by both dermal fibroblasts and synovial cells as well as collagenase production by the latter cell type. Thus, as for the sIL 1, a feedback mechanism exists for cell-associated IL 1-induced bioactivities.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2168857     DOI: 10.1016/S0171-2985(11)80295-0

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  6 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

2.  The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.

Authors:  D Burger; R Chicheportiche; J G Giri; J M Dayer
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

Review 3.  Treatment of rheumatoid arthritis with IL-1 inhibitors.

Authors:  C Gabay; W P Arend
Journal:  Springer Semin Immunopathol       Date:  1998

4.  The anesthetic management of children with neonatal-onset multi-system inflammatory disease.

Authors:  Christine F Lauro; Raphaela Goldbach-Mansky; Margaret Schmidt; Zenaide M N Quezado
Journal:  Anesth Analg       Date:  2007-08       Impact factor: 5.108

5.  Long-term Effect of Injection Treatment for Osteoarthritis in the Knee by Orthokin Autologous Conditioned Serum.

Authors:  Danial Zarringam; Joris E J Bekkers; Daniel B F Saris
Journal:  Cartilage       Date:  2017-11-25       Impact factor: 4.634

6.  A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer.

Authors:  Jean-Noel Gouze; Elvire Gouze; Glyn D Palmer; Victor S Liew; Arnulf Pascher; Oliver B Betz; Thomas S Thornhill; Christopher H Evans; Alan J Grodzinsky; Steven C Ghivizzani
Journal:  Arthritis Res Ther       Date:  2003-08-01       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.